U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462923) titled 'HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma' on Jan. 15.
Brief Summary: HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Study Start Date: Jan. 29
Study Type: INTERVENTIONAL
Condition:
Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Intervention:
DRUG: HS-20093 for inj...